Artiva Biotherapeutics, Inc.
Develops allogeneic, off-the-shelf NK cell therapies for cancer and autoimmune diseases.
ARTV | US
Overview
Corporate Details
- ISIN(s):
- N/A
- LEI:
- Country:
- United States of America
- Address:
- 5505 MOREHOUSE DRIVE, 92121 SAN DIEGO
- Website:
- https://www.artivabio.com/
Description
Artiva Biotherapeutics, Inc. is a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf natural killer (NK) cell-based therapies. The company's mission is to create effective, safe, and accessible cell therapies for patients with autoimmune diseases and cancer. Its lead product candidate, AlloNK® (AB-101), is a non-genetically modified, cryopreserved NK cell therapy. AlloNK® is being evaluated in clinical trials in combination with B-cell targeted monoclonal antibodies for the treatment of autoimmune diseases, including rheumatoid arthritis and Sjögren’s disease, and for various cancers. Artiva aims to overcome the limitations of complex and costly patient-specific cell therapies.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Artiva Biotherapeutics, Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Artiva Biotherapeutics, Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Artiva Biotherapeutics, Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
